The legal action, pending in the United States District Court for the Southern District of California, covers investors who purchased ARS Pharmaceuticals (SPRY) securities between March 9 and June 24, 2026. According to the complaint, management repeatedly anchored investor expectations to a July 1, 2026, effective date for expanded coverage. During a March earnings call, executives cited a rigid system at CVS Caremark but maintained that a substantial expansion was imminent. This narrative was reportedly reinforced on May 15, when the company stated it was in the final stages of the formulary approval process.
Investors Target ARS Pharmaceuticals Over Failed CVS Coverage Timeline
A securities class action lawsuit has been filed against ARS Pharmaceuticals following a 23.9% collapse in share price this summer. The litigation centers on allegations that the company misled shareholders regarding the timeline for securing expanded CVS Caremark insurance coverage for its allergy treatment, neffy.
The situation shifted abruptly on June 24, when the company revealed after the market closed that no new coverage decisions had been issued. The decision from CVS Caremark had been pushed to January 2027, effectively excluding neffy from expanded access during the peak summer and back-to-school allergy seasons. Following this disclosure, SPRY shares plummeted from $10.54 to $8.02 in a single day. Joseph E. Levi, lead counsel for the plaintiffs, asserts that the company failed to adequately disclose the risk of such a significant delay while simultaneously promising investors an imminent rollout. Shareholders have until October 5, 2026, to apply for lead plaintiff status in the case, which alleges violations of the Securities Exchange Act of 1934.
Comments (0)
No comments yet. Be the first!